Dr. Benjamin Jin, a biologist working on immunotherapy for HPV+ cancers, holds test tubes as he works in the lab of Dr. Christian Hinrichs, an investigator at the National Cancer Institute at the National Institutes of Health (NIH) in Bethesda, Maryland, February 7, 2018.
Experimental trials are ongoing at the National Institutes of Health Clinical Center, a US government-funded research hospital where doctors are trying to partially replace patients' immune systems with T-cells that would specifically attack cancers caused by the human papillomavirus (HPV), a common sexually transmitted infection. A person's T-cells will naturally try to kill off any invader, including cancer, but usually fall short because tumors can mutate, hide, or simply overpower the immune system.
Immunotherapies that have seen widespread success, such as chimeric antigen receptor (CAR-T) cell therapies, mainly target blood cancers like lymphoma, myeloma and leukemia, which have a tumor antigen -- like a flag or a signal -- on the surface of the cells so it is easy for immune cells to find and target the harmful cells. But many common cancers lack this clear, surface signal. Hinrichs' approach focuses on HPV tumors because they contain viral antigens that the immune system can easily recognize.
 / AFP PHOTO / SAUL LOEB        (Photo credit should read SAUL LOEB/AFP/Getty Images)
What you should do to prevent HPV
02:27 - Source: CNN
CNN  — 

Individuals with a cervix are now recommended to start cervical cancers screening at 25 and continue through age 65, with the primary human papillomavirus (HPV) testing every five years as the preferred method of testing, according to a new guideline released Thursday by the American Cancer Society.

The cervical cancer screening recommendations say that HPV testing in combination with a Pap test – also known as co-testing– every five years or a Pap test alone every three years are still acceptable options as not all laboratories have transitioned to the primary HPV testing.

The updated guideline appears in the ACS’s journal CA: A Cancer Journal for Clinician.

The ACS last updated its guideline in 2012 and recommended to start screening at age 21. In a statement, the organization explained that the decision to raise the age for cervical cancer screenings is due to new data that suggests vaccination has led to a drop in rates of precancerous cervical changes, which are the precursors to cancer.

Cervical cancer is low in the 20 to 24 year age group, and the numbers are expected to decrease as vaccine use increases, according to the ACS.

Debbie Saslow, the managing director of HPV & GYN Cancers for the ACS said the new “streamlined recommendations can improve compliance and reduce potential harms.”

“They are made possible by some important developments that have allowed us to transform our approach to cervical cancer screening, primarily a deeper understanding of the role of HPV and the development of tools to address it,” Saslow said in a press release.

Individuals who are 65 and older and have had an adequate negative result in prior screening can stop getting screened. Those with a hysterectomy can also discontinue screening after two consecutive negative HPV tests, two negative co-tests, or three negative Pap tests done within the past 10 years – with the most recent having occurred in the past three to five years. The ACS recommended that individuals who don’t have documentation of prior screening should continue getting screened until they have met this criteria.